PIXITMEDIA
Leading software-defined storage and data management solution provider, pixitmedia, a Kalray company, and Lenovo, the Fortune Global 500 technology powerhouse, are now offering a cost-effective and ultra-scalable cloud-enabled hyper-converged solution to the Media and Entertainment industry. Hyper-converged, or HCI, unites pixitmedia’s award-winning software, pixstor™ with ngenea®, with Lenovo’s smart solutions into a single appliance, with guaranteed performance suitable for a multitude of Media and Entertainment workflows.
Historically, studios have depended on storage products supplied by major data appliance vendors. Most vendors are either yet to evolve cloud-based solutions or offer very limited cloud capabilities. This is restrictive and limits the flexibility of media creation companies as their businesses grow and content delivery models change. Having a hyper-converged infrastructure gives studios the freedom to choose where to grow their capabilities, whether it be on-premise or in the cloud. Those working remotely should have the same experience as those who choose to work on-premises and vice versa. For companies operating virtual workstations, this is a vital part of the workflow, and it is where dynamic data management can bring huge benefits. A hyper-converged approach allows creative media businesses to stay agile and keep infrastructure costs low by virtualising key elements of conventional “hardware-defined” systems.
“pixitmedia and Lenovo liberate Media and Entertainment businesses from being locked into restrictive data environments. Studios that are able to quickly adjust infrastructure, keep up with productivity and meet content demands, are able to stay competitive. A hyper-converged approach enables creative media businesses of any size to stay agile and keep infrastructure costs lower" explains Ben Leaver, EVP of Business Development, pixitmedia.
“The Media and Entertainment sector is a complex and exciting industry and Lenovo is committed to working with partners to create solutions which offer customers value. In collaboration with pixitmedia we’ve developed a solution which makes it easy for companies in this sector to deploy a hyper-converged environment.” says Ian Jeffs, UK and Ireland General Manager, Lenovo Infrastructure Solutions Group.
The collaboration between pixitmedia and Lenovo has resulted in a Hyperconverged solution that guarantees customers complete control of their data. All users can see and access the same data securely, enabling rock-solid collaboration between multiple creative sites. The solution enables businesses a simplistic transition to cloud and hybrid ways of working with no disruption to existing workflows and no compromise on security, whilst delivering guaranteed ultra-fast performance. For ultimate flexibility, the pixitmedia HCI solution works with any cloud provider over a multitude of production workflows, giving the customer the flexibility to scale up or down according to projects. pixitmedia, a global leader in cloud-workflow solutions for Media and Entertainment, has already deployed multiple hybrid solutions to over 20 global media production and distribution companies.
The solution works seamlessly across multiple operating systems and leverages cloud providers’ networks for ultra-high-speed data transfers, businesses can easily expand on-premises pipelines into the cloud with a software-defined solution such as pixstor™, while still enjoying the guaranteed sustained collaboration, performance, scalability and intelligent management tools of an on-premises deployment. Supported by ngenea®, an intelligent data transport mechanism, business experiences can be tightly integrated on-premises, and cloud infrastructure integrated under a single namespace.
By adopting integrated cloud solutions such as ngenea® and pixstor™, media creation businesses will have everything that they need, from on-premises to remote working and everything in between. pixitmedia also offers an upgrade path for the HCI solution to scale-out NAS as your business grows to give customers that added flexibility for the future.
Working together with Lenovo is about driving business forward and empowering customer workflows. Hyper-converged infrastructure offers scalability and agility, optimised performance and collaboration and the option to reduce costs. In simple terms, it gives media enterprises more choices, more collaborative efficiencies and more freedom than ever before.
For more information on pixitmedia and Lenovo HCI solutions please visit: pixitmedia.com/lenovo/
ABOUT LENOVO
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$70 billion revenue global technology powerhouse, ranked #171 in the Fortune Global 500, employing 75,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver smarter technology for all, Lenovo has built on its success as the world’s leading PC player by expanding into new growth areas of infrastructure, mobile, solutions and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and sustainable digital society for everyone, everywhere.
ABOUT PIXITMEDIA
pixitmedia is a Kalray company (Euronext Growth Paris: ALKAL), a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge. pixitmedia and Kalray share a common vision and a complementary value proposition in both software and hardware to address today’s and tomorrow’s data-intensive world with solutions for a more intelligent, effective, energy-wise and user-friendly data-driven world.
pixitmedia’s award-winning purpose-built, software-defined storage and data solutions simplify the flow of data to connect an increasingly complex world. We devise optimized solutions that give customers both choice and freedom, our restless innovation constantly pushes boundaries and the unrivalled care and knowledge of our team ensure optimum performance and value. Customer success is at the heart of our business, we have technical specialists and a unique, dedicated lab facility to guarantee the effectiveness of our solutions. For more information, please visit https://pixitmedia.com or contact us: marketing@pixitmedia.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005654/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom